H

Hugel Inc
KOSDAQ:145020

Watchlist Manager
Hugel Inc
KOSDAQ:145020
Watchlist
Price: 272 500 KRW 3.22% Market Closed
Market Cap: 3T KRW
Have any thoughts about
Hugel Inc?
Write Note

P/E
Price to Earnings

25.4
Current
21.9
Median
23
Industry
Higher than median
Higher than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
25.4
=
Market Cap
2.8T KRW
/
Net Income
111.2B KRW
All Countries
Close
Market Cap P/E
KR
Hugel Inc
KOSDAQ:145020
2.8T KRW 25.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -178 533.6
US
Abbvie Inc
NYSE:ABBV
300.2B USD 59
US
Amgen Inc
NASDAQ:AMGN
159.1B USD 37.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
126.6B USD -263.9
US
Gilead Sciences Inc
NASDAQ:GILD
114.6B USD 910.1
US
Epizyme Inc
F:EPE
94.1B EUR -478.6
AU
CSL Ltd
ASX:CSL
137.3B AUD 33.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
87.6B USD 18.8
US
Seagen Inc
F:SGT
39.3B EUR -55.4
NL
argenx SE
XBRU:ARGX
34.1B EUR -129.9
Earnings Growth
KR
H
Hugel Inc
KOSDAQ:145020
Average P/E: 180.7
25.4
85%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -263.9
42%
US
Gilead Sciences Inc
NASDAQ:GILD
910.1
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.7
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.8
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
24.9
2-Years Forward
P/E
19.7
3-Years Forward
P/E
16.4

See Also

Discover More